面肩肱型肌营养不良研究中的肌肉影像学:范围综述与专家建议
本文为面肩肱型肌营养不良(FSHD)领域的范围综述与专家建议,系统检索PubMed、EMBASE和Cochrane Library数据库,筛选328项研究并纳入105项,评估MRI、超声和双能X线吸收法(DEXA)作为影像生物标志物的应用。MRI的肌内脂肪含量、STIR阳性和T2water指标用作诊断、预后和监测生物标志物;超声回声强度可作诊断及可能的预后和监测标志物;DEXA瘦肌肉量可作为附加监测标志物。作者基于专家意见提出路线图,以在多中心临床试验中优化各模态的使用。
要点
- MRI的肌内脂肪含量、STIR阳性和T2water指标可用作FSHD的诊断、预后和监测生物标志物。
- 超声回声强度可用作诊断生物标志物,并可能作为预后和监测生物标志物。
- DEXA瘦肌肉量可作为附加的监测生物标志物,各模态各有优势与挑战。
核心结论
- MRI的肌内脂肪含量、STIR阳性和T2water指标用作诊断、预后和监测生物标志物,超声回声强度可作诊断及可能的预后和监测标志物,DEXA瘦肌肉量可作为附加监测标志物。
- 作者基于专家意见提出路线图,以应对各影像模态的挑战,确保其在FSHD多中心临床试验中的最优使用。
研究设计与样本
- 研究类型为范围综述(scoping review),系统检索PubMed、EMBASE和Cochrane Library数据库,筛选328项研究,纳入105项。
- 由神经肌肉影像专家组基于专家意见形成建议,原文未报告证据分级方法。
关键影像表现/征象
- MRI指标包括肌内脂肪含量、STIR阳性和T2water,用于评估FSHD的疾病严重程度、活动度和进展。
- 超声以回声强度(echogenicity)评估肌肉,DEXA测量瘦肌肉量(lean muscle mass)。
诊断标准与关键数值
- 原文未报告敏感度、特异度、AUC、阈值或分级标准等具体诊断效能数值。
- MRI的肌内脂肪含量、STIR阳性和T2water被用作诊断、预后和监测生物标志物;超声回声强度用作诊断及可能的预后和监测生物标志物;DEXA瘦肌肉量可作为附加监测生物标志物。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Clinical trial readiness is an important topic in the field of facioscapulohumeral muscular dystrophy (FSHD). As FSHD is a slowly progressive and clinically heterogeneous disease, imaging biomarkers have been proposed to complement clinical outcome measures. Muscle magnetic resonance imaging (MRI), ultrasound and dual energy X-ray absorptiometry (DEXA) have been used to measure disease severity, activity and progression. We conducted a scoping review of the literature on these imaging modalities to assess gaps in knowledge and subsequently collaborated with a panel of neuromuscular imaging experts to generate recommendations on the road ahead. We systematically searched PubMed, EMBASE and Cochrane Library databases. Three-hundred and twenty-eight studies were screened and one hundred and five studies were included. MRI indices related to intramuscular fat content, STIR positivity and T2water are used as diagnostic as well as prognostic and monitoring biomarkers. Ultrasound echogenicity can be used as a diagnostic and potentially as a prognostic and monitoring biomarker. DEXA lean muscle mass may be used as an additional monitoring biomarker. Each imaging modality has its own benefits but also challenges. Based on our expert opinions, we propose a roadmap to address these challenges, ensuring the optimal use of each modality in multi-center clinical trials in FSHD.
引用
- Vincenten SCC, Teeselink S, Mul K, et al. Muscle imaging in facioscapulohumeral muscular dystrophy research: A scoping review and expert recommendations. Neuromuscul Disord. 2025. PMID: 39884029. doi:10.1016/j.nmd.2025.105274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。